Maika Hakimi-Klaiber
Duesseldorf, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Journal: Lancet (London, England)
Published: April 29, 2026
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.
Journal: Annals of hematology
Published: December 25, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2024
Engraftment Syndrome After Second Autologous Stem Cell Transplantation for Myeloma: A Case Report.
Journal: Case reports in hematology
Published: November 27, 2024
Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy.
Journal: Hematology reports
Published: May 19, 2024
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Journal: The Lancet. Haematology
Published: June 11, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026